Wie sind die Öffnungszeiten?

Montag 09:00 - 18:00 Dienstag 09:00 - 18:00 Mittwoch 09:00 - 18:00 Donnerstag 09:00 - 18:00 Freitag 09:00 - 18:00

TVNS Health, Südliche Münchner Str. 62, Grünwald (2026)

26/12/2025

A medical-device approach to everyday neuromodulation.
tVNS® is the only non-invasive vagus nerve stimulator that meets Class IIa medical-device standards under EU-MDR.

This distinction reflects a central principle in neuromodulation: precision matters. Unlike general ear stimulation or indirect methods, tVNS® is engineered to target the cymba co**ha — the only auricular zone with verified vagal innervation.

By focusing on a validated neural pathway connected to the nucleus tractus solitarii, tVNS® delivers controlled neuromodulation without surgery or medication. It adapts the clinical VNS mechanism into a safe, everyday-use medical device supported by a continually expanding body of peer-reviewed research.

Across fields such as depression, autonomic regulation, fear processing, stress modulation, and emotional recognition, clinical studies continue to explore the therapeutic potential of auricular vagus nerve stimulation. This growing evidence underscores the importance of rigorous device design and anatomical accuracy when applying neuromodulation outside the operating room.

Learn more about the science and regulatory foundations behind tVNS® at www.tvns.health

19/12/2025

A structured, evidence-informed approach to non-invasive neuromodulation.

tVNS® is designed as a certified medical device, developed to stimulate the cymba co**ha — the only auricular region with verified vagal innervation. This targeted approach allows stimulation to engage pathways connected to the nucleus tractus solitarii, a key brainstem hub involved in autonomic regulation.

Over the past two decades, clinical research has continued to explore the potential applications of auricular vagus nerve stimulation in areas such as autonomic balance, emotional processing, and neurological conditions. As this body of evidence grows, tVNS® remains focused on delivering neuromodulation within a regulated, non-invasive medical-device framework that prioritizes accuracy, safety, and accessibility.

Our goal is to support individuals and clinicians with a scientifically grounded option for exploring vagus nerve stimulation in everyday life.

Learn more about tVNS® and its clinical foundations at www.tvns.health

09/12/2025

Clinical evidence in migraine management.

In a controlled 12-week treatment period, patients using the tVNS® Vagus Nerve Stimulation Device experienced a reduction of 50% in the frequency of days with migraines. These findings contribute to a growing body of research exploring how targeted auricular vagus nerve stimulation may support individuals affected by recurrent migraine episodes.

Migraine is a complex neurological condition involving dysregulation across pain pathways, autonomic balance, and central nervous system activity. By stimulating the cymba co**ha — the only auricular region with verified vagal innervation — tVNS® engages pathways connected to the nucleus tractus solitarii, a key relay center involved in autonomic modulation.

While responses vary and research continues to evolve, these results highlight an important direction for non-invasive neuromodulation in migraine care.

Learn more about the ongoing research behind tVNS® at www.tvns.health

01/12/2025

tVNS® in Focus: A Growing Global Conversation
Transcutaneous vagus nerve stimulation is increasingly being recognised not only in academic and clinical circles, but also by major media outlets across Europe and beyond.

Publications and broadcasters such as the BBC, Süddeutsche Zeitung, ARD, Deutschlandfunk, Nürnberger Nachrichten, and the Daily Mail have all reported on tVNS® — exploring its role in neuromodulation, its use in ongoing clinical trials, and its potential relevance for conditions such as tinnitus, depression, long COVID, chronic fatigue, and sleep disorders.

This attention reflects a broader shift:
Patients, researchers, and healthcare providers are actively seeking evidence-based alternatives for managing chronic and treatment-resistant conditions.

The increasing public visibility of tVNS® is not a marketing success — it's a sign that important clinical conversations are reaching wider audiences. We welcome the scrutiny, the dialogue, and the opportunity to keep building a future in which neuromodulation is more accessible, more transparent, and more patient-centred.

More about our work, scientific partnerships, and published data at www.tvns.health

28/11/2025

A published case report in the European Journal of Epilepsy describes a 24-year-old woman with drug-resistant epilepsy who achieved long-term seizure freedom after starting Transcutaneous Vagus Nerve Stimulation (tVNS®).

Following years of unsuccessful medication treatments, she began tVNS® therapy and experienced complete seizure control within two months — remaining seizure-free for more than 56 months. Researchers also observed notable psychosocial improvements, including restored independence and quality of life.

𝘚𝘰𝘶𝘳𝘤𝘦: 𝘌𝘶𝘳𝘰𝘱𝘦𝘢𝘯 𝘑𝘰𝘶𝘳𝘯𝘢𝘭 𝘰𝘧 𝘌𝘱𝘪𝘭𝘦𝘱𝘴𝘺 (2019), 𝘚𝘦𝘪𝘻𝘶𝘳𝘦 𝘍𝘳𝘦𝘦𝘥𝘰𝘮 𝘸𝘪𝘵𝘩 𝘛𝘳𝘢𝘯𝘴𝘤𝘶𝘵𝘢𝘯𝘦𝘰𝘶𝘴 𝘝𝘢𝘨𝘢𝘭 𝘕𝘦𝘳𝘷𝘦 𝘚𝘵𝘪𝘮𝘶𝘭𝘢𝘵𝘪𝘰𝘯 𝘪𝘯 𝘋𝘳𝘶𝘨-𝘙𝘦𝘴𝘪𝘴𝘵𝘢𝘯𝘵 𝘌𝘱𝘪𝘭𝘦𝘱𝘴𝘺

Discover more about clinical research on tVNS® at www.tvns.health

24/11/2025

Behind every breakthrough in neuromodulation stands rigorous research.

The tVNS® research device is trusted by leading institutions worldwide because it is designed specifically to meet the needs of clinical and scientific studies. With features such as:

- Approved Medical Device
- Wireless Connectivity & Programmability
- Triggered stimulation
- Titanium-Iridium Electrode
- GDPR-Compliant Data Processing
- SHAM mode
- Support for Clinical Trials

These capabilities make tVNS® a preferred choice for researchers exploring the therapeutic potential of non-invasive vagus nerve stimulation.

By bridging clinical standards with innovative design, tVNS® continues to support cutting-edge studies that shape the future of healthcare.

Discover more about our research solutions at www.tvns.health

20/11/2025

A published case report in the European Journal of Epilepsy describes a 24-year-old woman with drug-resistant epilepsy who achieved long-term seizure freedom after starting Transcutaneous Vagus Nerve Stimulation (tVNS®).

Following years of unsuccessful medication treatments, she began tVNS® therapy and experienced complete seizure control within two months — remaining seizure-free for more than 56 months. Researchers also observed notable psychosocial improvements, including restored independence and quality of life.

Source: European Journal of Epilepsy (2019), Seizure Freedom with Transcutaneous Vagal Nerve Stimulation in Drug-Resistant Epilepsy

Discover more about clinical research on tVNS® at www.tvns.health

19/11/2025

tVNS® in Osteoarthritis Research: A New Direction for Pain Modulation

A 2025 pilot trial, published in Osteoarthritis and Cartilage Open, investigated the safety and preliminary effects of auricular tVNS® for individuals living with chronic knee osteoarthritis.

Thirty participants received a single 60-minute session of ear-based vagus nerve stimulation. The results:

• The treatment was well tolerated
• No adverse events were reported
• Early data showed a clinically meaningful reduction in knee pain scores

Unlike conventional joint-targeted treatments, this approach modulates central pain processing via the vagus nerve — targeting the brain, not the joint.

The findings suggest that tVNS® may offer a safe, non-invasive option for patients with chronic pain, with larger clinical trials already underway.

Read the full study at: www.oarsiopenjournal.com

17/11/2025

Trusted by the world's leading institutions.

From the NHS to Cornell University, tVNS® is used and studied by clinics, research centers, and institutions across Europe and North America.

Our technology is designed to support patients living with complex neurological and physiological conditions, including tinnitus, chronic pain, long COVID, depression, and sleep disorders.

Every device is backed by published scientific research and strong clinical confidence.

Better days are ahead, grounded in evidence.

Explore more at www.tvns.health

13/11/2025

tVNS® is a certified medical device, clinically proven and entirely non-invasive, designed to stimulate the vagus nerve safely and effectively through the ear.

The vagus nerve plays a crucial role in regulating the autonomic nervous system, influencing functions such as stress regulation, focus, recovery, and overall balance in brain-body communication. By integrating tVNS® into daily routines, patients can access a modern, evidence-based therapy that requires no drugs or surgery and is supported by extensive clinical research.

This technology has been studied across multiple fields — from neurology to psychiatry — and is already trusted by institutions worldwide. Its ease of use allows both healthcare professionals and patients to adopt it as part of individualized therapy concepts, supporting a new standard of care.

tVNS® demonstrates how medical innovation can be translated into practical solutions, giving patients access to effective neuromodulation with science at its core.

31/10/2025

Did you know that 15 million Europeans will experience at least one seizure in their lifetime, and more than 6 million people in Europe live with epilepsy? Behind these numbers are individuals and families navigating daily uncertainty, often searching for better solutions beyond conventional treatments.

This is where innovation matters. tVNS® is being studied as a non-invasive approach that targets the vagus nerve to support seizure management and improve quality of life. By harnessing the body's own neurological pathways, it represents a potential step forward in addressing one of the most widespread neurological conditions.

Discover more about the science and clinical evidence at www.tvns.health

30/10/2025

Why are more Parkinson's patients exploring tVNS®?

Because recent clinical research is showing early promise and measurable results. A randomized study demonstrated that active tVNS® therapy improved gait characteristics such as step length, stride velocity, and balance in Parkinson's patients, while also showing positive effects on cortical activity in the brain.

Unlike invasive approaches, tVNS® is completely non-surgical and medically certified under EU MDR—making it a safe, non-invasive option that can complement existing therapies.

While research continues, the findings highlight the potential of tVNS® to support patients in improving mobility and quality of life.

Learn more about the science behind tVNS® at www.tvns.health

TVNS Health

26/12/2025

19/12/2025

09/12/2025

01/12/2025

28/11/2025

24/11/2025

20/11/2025

19/11/2025

17/11/2025

13/11/2025

31/10/2025

30/10/2025

Adresse

Öffnungszeiten

Telefon

Webseite

Benachrichtigungen

Die Praxis Kontaktieren

Verknüpfungen

Teilen

Kategorie

Montag	09:00 - 18:00
Dienstag	09:00 - 18:00
Mittwoch	09:00 - 18:00
Donnerstag	09:00 - 18:00
Freitag	09:00 - 18:00